NCT06914908 - Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

January 29, 2031

Study Completion Date

January 29, 2031

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Interventions

DRUG

lunsekimig

Pharmaceutical form: solution for injection Route of administration: subcutaneous

DRUG

Mometasone furoate nasal spray (MFNS)

Pharmaceutical form: Intranasal spray Route of administration: intranasal

Trial Locations (8)

RECRUITING

Investigational Site Number : 0320002, Rosario

RECRUITING

Investigational Site Number : 0320003, Mendoza

RECRUITING

ENT Associates of Texas - McKinne- Site Number : 8400014, McKinney

RECRUITING

Alamo ENT Associates- Site Number : 8400001, San Antonio

RECRUITING

Treasure Valley Medical Research- Site Number : 8400002, Boise

RECRUITING

Allergy & Rheumatology- Site Number : 8400005, La Jolla

RECRUITING

Investigational Site Number : 0320001, Buenos Aires

RECRUITING

Investigational Site Number : 8260001, Newcastle upon Tyne